Stock 300630 HAINAN POLY PHARM. CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Company Hainan Poly Pharm. Co., Ltd

Equities

300630

CNE100002N10

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
12.35 CNY -18.75% Intraday chart for Hainan Poly Pharm. Co., Ltd -15.00% -45.40%
Apr. 08 Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden MT
Apr. 04 Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany MT

Business Summary

Hainan Poly Pharm Co Ltd is a company engaged in research and development, production and sales of drugs. The Company operates five segments. The Anti-Allergic segment is engaged in the production of desloratadine dispersible tablets, desloratadine dry suspension and desloratadine tablets. The Antibiotic segment provides levofloxacin hydrochloride capsules and azithromycin dry suspension for the treatment of bacterial infections. The Nonsteroidal Anti-inflammatory Drugs segment provides diclofenac sodium enteric-coated sustained-release capsule products for the treatment of arthritis and dysmenorrhea. The Digestive segment is involved in providing trimebutine maleate tablets to treat abdominal pain, diarrhea, and irritable bowel syndrome. The Company also operates Other segment.

Number of employees: 1,522

Sales per Business

CNY in Million2021Weight2022Weight Delta
Antibiotics
24.1 %
447 29.6 % 435 24.1 % -2.72%
Cardiovascular Drugs
18.3 %
266 17.6 % 331 18.3 % +24.34%
Antiallergic Drugs
14.5 %
294 19.5 % 262 14.5 % -10.80%
Gastrointestinal Drugs
13.1 %
155 10.3 % 236 13.1 % +52.06%
Others
10.0 %
150 9.9 % 180 10.0 % +20.48%
First Aid Medicine
9.1 %
- - 164 9.1 % -
Non-steroidal Anti-inflammatory Drugs
7.1 %
119 7.9 % 129 7.1 % +8.55%
Dermatological Drugs
3.9 %
79 5.2 % 70 3.9 % -11.51%

Sales per region

CNY in Million2021Weight2022Weight Delta
China
83.7 %
1,277 84.7 % 1,511 83.7 % +18.30%
International
16.3 %
231 15.3 % 295 16.3 % +27.57%

Managers

Managers TitleAgeSince
Min Hua Fan CEO
 Chief Executive Officer 63 92-07-13
Tong Ning Luo DFI
 Director of Finance/CFO 49 04-09-30
Ji Ping Wang BRD
 Director/Board Member 52 10-06-30
Mao Zhou BRD
 Director/Board Member 54 12-09-30
Hui Fang Xie BRD
 Director/Board Member 43 04-09-30
Shi Jun Wu IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Shu Ge Jiao BRD
 Director/Board Member 58 15-05-31
Min Hua Fan CEO
 Chief Executive Officer 63 92-07-13
Hui Fang Xie BRD
 Director/Board Member 43 04-09-30
Mao Zhou BRD
 Director/Board Member 54 12-09-30
Tong Ning Luo DFI
 Director of Finance/CFO 49 04-09-30
Ji Ping Wang BRD
 Director/Board Member 52 10-06-30
Ya Dong Chen BRD
 Director/Board Member 54 18-11-25
De Zhu Fan BRD
 Director/Board Member 58 18-11-25
Yu Ding CHM
 Chairman 43 08-11-30
Lei Pan BRD
 Director/Board Member 40 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 455,008,088 261,896,449 ( 57.56 %) 3,232,923 ( 0.7105 %) 57.56 %

Shareholders

NameEquities%Valuation
Min Hua Fan
11.49 %
37,014,877 11.49 % 91 M ¥
Xiao Ping Zhu
9.633 %
31,026,544 9.633 % 77 M ¥
Citic Securities Co., Ltd. (Invt Port)
3.334 %
10,739,715 3.334 % 26 M ¥
Zhong Ou Asset Management Co., Ltd
2.600 %
8,374,769 2.600 % 21 M ¥
Li Hui Duan
1.552 %
5,000,000 1.552 % 12 M ¥
Golden Trust Sinopac Fund Management Co., Ltd.
1.534 %
4,941,576 1.534 % 12 M ¥
HAINAN POLY PHARM. CO., LTD
1.301 %
4,191,623 1.301 % 10 M ¥
Fullgoal Fund Management Co., Ltd.
1.174 %
3,779,736 1.174 % 9 M ¥
Bang Yi Luo
0.9438 %
3,039,959 0.9438 % 7 M ¥
Dajia Life Insurance Co. Ltd.
0.9089 %
2,927,493 0.9089 % 7 M ¥
NameEquities%Valuation
Min Hua Fan
97.18 %
111,044,632 97.18 % 274 M ¥

Holdings

NameEquities%Valuation
HAINAN POLY PHARM. CO., LTD
1.30%
 4,191,623 1.30% 10,340,650 $

Company contact information

Hainan Poly Pharm. Co., Ltd.

Guilinyang Economic Dev Zone Meilan District

571127, Haikou

+

http://www.hnpoly.com
address Hainan Poly Pharm. Co., Ltd(300630)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Hainan Poly Pharm. Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.35
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HAINAN POLY PHARM. CO., LTD Stock Hainan Poly Pharm. Co., Ltd
-45.40% 765M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300630 Stock
  4. Company Hainan Poly Pharm. Co., Ltd